Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Boehringer Ingelheim
Moodys
Accenture
UBS
Federal Trade Commission
Mallinckrodt
Chubb
Dow
Express Scripts

Generated: February 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 050797

« Back to Dashboard

NDA 050797 describes ZMAX, which is a drug marketed by Pf Prism Cv and is included in one NDA. It is available from two suppliers. There are three patents protecting this drug. Additional details are available on the ZMAX profile page.

The generic ingredient in ZMAX is azithromycin. There are thirty-two drug master file entries for this compound. Fifty-seven suppliers are listed for this compound. Additional details are available on the azithromycin profile page.
Summary for 050797
Tradename:ZMAX
Applicant:Pf Prism Cv
Ingredient:azithromycin
Patents:3
Therapeutic Class:Antibacterials
Formulation / Manufacturing:see details
Pharmacology for NDA: 050797
Ingredient-typeMacrolides
Medical Subject Heading (MeSH) Categories for 050797
Suppliers and Packaging for NDA: 050797
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ZMAX azithromycin FOR SUSPENSION, EXTENDED RELEASE;ORAL 050797 NDA Pfizer Laboratories Div Pfizer Inc 0069-4170 N 0069-4170-34
ZMAX azithromycin FOR SUSPENSION, EXTENDED RELEASE;ORAL 050797 NDA Rebel Distributors Corp 21695-444 E 21695-444-60

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:FOR SUSPENSION, EXTENDED RELEASE;ORALStrengthEQ 2GM BASE/BOT
Approval Date:Jun 10, 2005TE:RLD:Yes
Patent:➤ Sign UpPatent Expiration:Jul 31, 2018Product Flag?Substance Flag?YDelist Request?
Patent:➤ Sign UpPatent Expiration:Feb 14, 2024Product Flag?YSubstance Flag?Delist Request?
Patented Use:METHOD OF TREATING BACTERIAL INFECTIONS
Patent:➤ Sign UpPatent Expiration:Feb 14, 2024Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 050797

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pf Prism Cv ZMAX azithromycin FOR SUSPENSION, EXTENDED RELEASE;ORAL 050797-001 Jun 10, 2005 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Moodys
Federal Trade Commission
Cipla
Argus Health
Queensland Health
McKesson
McKinsey
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot